Thursday 15 October 2026 Export ELDN’s income statement to Excel — free account

Eledon Pharmaceuticals, Inc.

In the quarter to June 2026, EPS fell 107.7% and free cash flow fell 28.0%, each against the same quarter a year earlier.

2.27 0.02 +0.89%

Follow ELDN

Alert me

Market cap: $190.2M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 29.22%

Capital & Financial Ratios $m

Market Cap 190.15

Revenue —

Net Income (98.56)

Free Cash Flow (73.86)

Net Debt (88.76)

Current Ratio 7.90

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 7.81

Past 5Y EPS Growth —

This Y EPS Growth (82.69%)

Next Y EPS Growth 12.63%

Next Y revenue growth —

Next 5Y EPS Growth (17.33%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 94.40%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	51	140	133	89
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	56	144	136	93

	2023	2024	2025	Q'26
Payables	1	6	4	3
ST’ Debt	—	—	—	—
Other	—	—	—	—
	4	12	18	12

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	8.28%	(6.42%)	17.56%

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(23)	(23)	—	—	—
’25	(16)	(18)	(14)	(14)	(62)
’24	(9)	(8)	(12)	(19)	(47)
’23	(10)	(8)	(12)	(9)	(40)
’22	(8)	(6)	(5)	(9)	(28)
’21	(5)	(7)	(7)	(9)	(29)
’20	(2)	(3)	(1)	(9)	(15)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(23)	(23)	—	—	—
’25	(16)	(18)	(14)	(14)	(62)
’24	(9)	(8)	(12)	(19)	(47)
’23	(10)	(8)	(12)	(9)	(40)
’22	(8)	(6)	(5)	(9)	(28)
’21	(5)	(7)	(7)	(9)	(29)
’20	(2)	(3)	(1)	(9)	(15)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.33)	(0.27)	—	—	—
’25	(0.08)	(0.13)	(0.21)	(0.10)	(0.52)
’24	(0.79)	(1.06)	1.39	(0.64)	(0.75)
’23	(0.75)	(2.74)	(0.35)	(0.29)	(4.73)
’22	(0.69)	(0.65)	(0.73)	(4.09)	(6.16)
’21	(0.57)	(0.50)	(0.66)	(0.59)	(2.33)
’20	(8.45)	(2.70)	(5.51)	1.06	(15.72)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	117.61	61.56	27.36	7.20	4.50	3.81	2.03	1.07	1.52	1.35	Analyst estimates 2026–2028 Powerpack
	High	1,425.60	181.44	154.98	93.78	27.32	22.91	5.14	3.70	5.54	4.98
People
People	Employees	8	7	10	8	10	12	17	20	31	33
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—
	EBT	(6)	(13)	(14)	(16)	(23)	(37)	(88)	(117)	(36)	(46)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	(6)	(13)	(14)	(16)	(23)	(35)	(88)	(117)	(36)	(46)
	Depreciation	0	0	0	2	0	0	49	0	0	—
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	(271.43)	(41.37)	(28.06)	(24.46)	(15.72)	(2.33)	(6.16)	(4.73)	(0.75)	(0.52)
	Cash flow	(231.13)	(57.44)	(23.75)	(21.12)	(10.48)	(1.95)	(1.99)	(1.61)	(0.97)	(0.76)
	Capex	0.05	0.03	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Free cash flow	(231.08)	(57.41)	(23.75)	(21.12)	(10.48)	(1.95)	(1.99)	(1.61)	(0.97)	(0.76)
	Book value	(126.85)	74.79	28.94	14.43	131.35	11.07	5.89	0.29	2.43	1.67
	Shares, m	0	0	1	1	1	15	14	25	49	82
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(5)	(15)	(12)	(14)	(15)	(29)	(28)	(40)	(47)	(62)
	Capex	0	0	—	—	—	—	—	—	—	—
	Free cash flow	(5)	(15)	(12)	(14)	(15)	(29)	(28)	(40)	(47)	(62)
Balance, $m
Balance, $m	Working capital	(3)	18	12	9	113	84	53	52	132	117
	Total debt	3	—	—	0	0	1	1	—	—	—
	Net debt	2	(17)	(13)	(9)	(114)	(85)	(56)	(51)	(140)	(133)
	Shareholders’ equity	(3)	19	14	9	191	164	84	7	118	137
Returns, %
Returns, %	ROA	(16.35)	(118.76)	(74.19)	(114.54)	(21.92)	(18.77)	(66.81)	(128.16)	(27.16)	(26.34)
	ROIC	0.00	(381.60)	(578.13)	(1,488.41)	(15.11)	(29.11)	(198.99)	0.00	0.00	(1,511.24)
	ROE	(19.17)	(156.79)	(82.87)	(133.66)	(22.80)	(19.46)	(70.89)	(652.92)	(518.40)	(63.56)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
PRQR ProQR Therapeutics N.V.	$196.1M	— (loss-making)	— (loss-making)	+135.03% (above 0%: growing)	n/m	−1.06% (below 0%: shrinking)	100.00%	(100.72%)	Compare
LYEL Lyell Immunopharma, Inc.	$195.8M	— (loss-making)	— (loss-making)	−50.00% (below 0%: shrinking)	n/m	+1.31% (above 0%: growing)	100.00%	(1,183,425.00%)	Compare
RNAC Cartesian Therapeutics, Inc.	$191.8M	— (loss-making)	— (loss-making)	−92.91% (below 0%: shrinking)	−7.84% (below 0%: shrinking)	−6.15% (below 0%: shrinking)	100.00%	0.00%	Compare
ACOG Alpha Cognition Inc.	$191.7M	— (loss-making)	—	+267.56% (above 0%: growing)	n/m	−109.25% (below 0%: shrinking)	94.80%	(127.29%)	Compare
IVVD Invivyd, Inc.	$190.4M	— (loss-making)	— (loss-making)	+21.20% (above 0%: growing)	n/m	−226.89% (below 0%: shrinking)	91.09%	(320.76%)	Compare
ELDN Eledon Pharmaceuticals, Inc.	$190.2M	— (loss-making)	—	—	n/m	−28.02% (below 0%: shrinking)	0.00%	0.00%
CGEN Compugen Ltd.	$187.6M	5.5×	— (loss-making)	+107.00% (above 0%: growing)	n/m	−155.42% (below 0%: shrinking)	(3.54%)	(339.62%)	Compare
UPB Upstream Bio, Inc.	$187.3M	— (loss-making)	— (loss-making)	−17.50% (below 0%: shrinking)	n/m	+9.33% (above 0%: growing)	100.00%	(5,480.98%)	Compare
SION Sionna Therapeutics, Inc.	$185.0M	— (loss-making)	—	—	n/m	−22.40% (below 0%: shrinking)	—	0.00%	Compare
Median of peers	$191.0M	—	—	+21.20%	—	−14.27%	100.00%	(224.02%)

All 614 Biotechnology stocks →

Eledon Pharmaceuticals, Inc. (ELDN) key facts

Eledon Pharmaceuticals, Inc. (ELDN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 15, 2026, ELDN traded at $2.27, a market capitalization of $190.2 million.
Return on equity was −63.6% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.